Shanghai, China

Liuyu Dong

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Gannex Pharma Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liuyu Dong - Innovator in FXR Modulation

Introduction

Liuyu Dong is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of FXR activity. His innovative work has led to the development of a unique compound that holds promise for various therapeutic applications.

Latest Patents

Liuyu Dong holds 1 patent for his invention titled "Compounds for modulating activity of FXR and uses thereof." This patent provides a compound designed to modulate the activity of FXR, featuring a specific structure outlined in formula (I). The invention also includes pharmaceutically acceptable salts, esters, or stereoisomers of the compound, showcasing its versatility in potential applications.

Career Highlights

Throughout his career, Liuyu Dong has worked with Gannex Pharma Co., Ltd., where he has contributed to various research initiatives. His expertise in pharmaceutical development has positioned him as a valuable asset in the industry.

Collaborations

Liuyu Dong has collaborated with notable professionals in his field, including Gudmundsson Kristjan and Bailing Yang. These partnerships have further enhanced his research and development efforts.

Conclusion

Liuyu Dong's innovative work in FXR modulation exemplifies the impact of dedicated inventors in the pharmaceutical industry. His contributions continue to pave the way for advancements in therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…